Skip to content

After viral rebound, dolutegravir-based treatment more likely to suppress HIV

Dr Andrew Hill presenting at HIV Glasgow 2022. Image by Alan Donaldson Photography.

CD4 and white blood cell declines caused by islatravir are dose-related and reversible, but rule out using it for prevention

Todd Correll presenting at HIV Glasgow 2022. Image by Alan Donaldson Photography.

Rapid scale-up of PrEP in Ukraine this year, despite the war

Chernihiv AIDS Center after being hit by a missile. Image from Sergiy Antoniak's EACS Standard of Care meeting presentation.

People with HIV not getting medication to prevent heart disease, despite high risk

Nadine Jaschinski presenting at HIV Glasgow 2022. Image by Alan Donaldson Photography.

So far, Poland has seen fewer Ukrainian refugees with HIV than expected

Dr Miłosz Parczewski presenting at HIV Glasgow 2022. Image by Alan Donaldson Photography.

COVID-19 vaccine and booster highly effective in people with HIV, large studies show

SeventyFour/Shutterstock.com

Stigma and discrimination against people with HIV are as big an issue as ever

Teymur Noori at the EACS Standard of Care meeting. Photo by Bernard de Keyzer.

Low-level HIV and viral load blips are important warning signals, European study finds

Jarun Ontakrai/Shutterstock.com

Communities in Africa twice as likely to have HIV when mines open nearby

Sunshine Seeds/Shutterstock.com